medbioМедико-биологические проблемы жизнедеятельностиMedical and Biological Problems of Life Activity2074-2088Республиканский научно-практический центр радиационной медицины и экологии человекаmedbio-131Research ArticleКЛИНИЧЕСКАЯ МЕДИЦИНАCLINICAL MEDICINEПрепятствия на пути внедрения вакцинации против ВПЧ-инфекцииDifficulties on the way to introducing HPV vaccinationКорсакЕ. С.KorsakK. S.noemail@neicon.ruВоропаевЕ. В.VoropaevE. V.noemail@neicon.ruУО «Гомельский государственный медицинский университет»Russian Federation2022020320230199104Copyright © Корсак Е.С., Воропаев Е.В., 20232023Корсак Е.С., Воропаев Е.В.Korsak K.S., Voropaev E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://medbio.ejournal.by/jour/article/view/131

В отношении рака шейки матки, который в 99,7% случаев вызывает вирус папилломы человека (ВПЧ), первичной профилактикой является вакцинация от данной инфекции. Вакцины от ВПЧ, доступные на сегодняшний день, безопасны и эффективны. Страны, которые внесли вакцину от ВПЧ в свой Национальный календарь, регистрируют снижение заболеваемости раком шейки матки и другими онкозаболеваниями, которые вызывает вирус папилломы человека. Однако на пути внедрения вакцины существует ряд препятствий. В статье проанализированы основные сдерживающие факторы для массовой вакцинации от ВПЧ.

For cervical cancer, which in 99.7% of cases is caused by human papillomavirus (HPV), the primary prevention is vaccination against the infection. The HPV vaccines available today are safe and effective. Countries that have added HPV vaccine to their National Calendar have reported decreases in cervical cancer and other cancers caused by the human papillomavirus. However, there are a number of obstacles to the introduction of the vaccine. This article analyzes the main barriers to mass HPV vaccination.

ВПЧрак шейки маткивакцинацияотношение к вакцинацииHPVcervical cancervaccinationattitude to vaccinationReferencesAffordable human papillomavirus screening needed to eradicate cervical cancer for all / S. Krivacsy [et al.] // The Lancet Global Health. - 2019. - Vol. 7, No 12. - P. 1605-1606. doi: 10.1016/S2214-109X(19)30423-1Affordable human papillomavirus screening needed to eradicate cervical cancer for all / S. Krivacsy [et al.] // The Lancet Global Health. - 2019. - Vol. 7, No 12. - P. 1605-1606. doi: 10.1016/S2214-109X(19)30423-1HPV vaccines can be the hallmark of cancer prevention / S. Sanjose [et al.] // The Lancet. - 2019. - Vol. 394, No 10197. - P. 450-451. doi: 10.1016/S0140-6736(19)30549-5HPV vaccines can be the hallmark of cancer prevention / S. Sanjose [et al.] // The Lancet. - 2019. - Vol. 394, No 10197. - P. 450-451. doi: 10.1016/S0140-6736(19)30549-5Assessment of eight HPV vaccination programs implemented in lowest income countries /j. Ladner [et al.] // BMC Public Health. - 2012. - Vol. 12. - P. 370. doi: 10.1186/1471-2458-12-370Assessment of eight HPV vaccination programs implemented in lowest income countries /j. Ladner [et al.] // BMC Public Health. - 2012. - Vol. 12. - P. 370. doi: 10.1186/1471-2458-12-370Вакцины и вакцинация. Национальное руководство. Краткое издание / под ред. В.В. Зверева, Р.М. Хаитова. - Мщсква : ГЭОТАР-Медиа, 2014. - 640 с.Вакцины и вакцинация. Национальное руководство. Краткое издание / под ред. В.В. Зверева, Р.М. Хаитова. - Мщсква : ГЭОТАР-Медиа, 2014. - 640 с.Discrepancies in the evaluation of the safety of the human papillomavirus vaccine /j.L. Cervantes [et al.] // Memorias do Instituto Oswaldo Cruz. - 2018. - Vol. 113, No 8. - P. 180063. doi: 10.1590/0074-02760180063Discrepancies in the evaluation of the safety of the human papillomavirus vaccine /j.L. Cervantes [et al.] // Memorias do Instituto Oswaldo Cruz. - 2018. - Vol. 113, No 8. - P. 180063. doi: 10.1590/0074-02760180063Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials / M. Arbyn [et al.] // Expert Review Vaccines. - 2018. - Vol. 17, No 12. - P. 1085-1091. doi: 10.1080/14760584.2018.1548282Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials / M. Arbyn [et al.] // Expert Review Vaccines. - 2018. - Vol. 17, No 12. - P. 1085-1091. doi: 10.1080/14760584.2018.1548282Is HPV vaccination in pregnancy safe? / U. Bonde [et al.] Human Vaccines & Immunotherapeutics. - 2016. - Vol. 12, No 8. - P. 1960-1964. doi:10.1080/21645515.2016.1160178Is HPV vaccination in pregnancy safe? / U. Bonde [et al.] Human Vaccines & Immunotherapeutics. - 2016. - Vol. 12, No 8. - P. 1960-1964. doi:10.1080/21645515.2016.1160178Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy / F. Carozzi [et al.] // BMC Infectious Diseases. - 2018. - Vol. 18, No 1. - P. 38. doi: 10.1186/s12879-018-2945-8Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy / F. Carozzi [et al.] // BMC Infectious Diseases. - 2018. - Vol. 18, No 1. - P. 38. doi: 10.1186/s12879-018-2945-8Non-Vaccine-Type Human Papillomavirus Prevalence After Vaccine Introduction: No Evidence for Type Replacement but Evidence for Cross-Protection / M. Saccucci [et al.] // Sexually Transmitted Diseases. - 2018. - Vol. 45, no 4. - P. 260-265. doi: 10.1097/OLQ.0000000000000731Non-Vaccine-Type Human Papillomavirus Prevalence After Vaccine Introduction: No Evidence for Type Replacement but Evidence for Cross-Protection / M. Saccucci [et al.] // Sexually Transmitted Diseases. - 2018. - Vol. 45, no 4. - P. 260-265. doi: 10.1097/OLQ.0000000000000731The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? / C. Patel [et al.] // Eurosurveillance. - 2018. - Vol. 23, No 41. - P. 1700737. doi: 10.2807/1560-7917.ES.2018.23.41.1700737The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? / C. Patel [et al.] // Eurosurveillance. - 2018. - Vol. 23, No 41. - P. 1700737. doi: 10.2807/1560-7917.ES.2018.23.41.1700737Substantial Decline in Prevalence of Vaccine-Type and Nonvaccine-Type Human Papillomavirus (HPV) in Vaccinated and Unvaccinated Girls 5 Years After Implementing HPV Vaccine in Norway / B. Feiring [et al.] // The Journal of Infectious Diseases. - 2018. - Vol. 218, No 12. - P. 1900-1910. doi: 10.1093/infdis/jiy432Substantial Decline in Prevalence of Vaccine-Type and Nonvaccine-Type Human Papillomavirus (HPV) in Vaccinated and Unvaccinated Girls 5 Years After Implementing HPV Vaccine in Norway / B. Feiring [et al.] // The Journal of Infectious Diseases. - 2018. - Vol. 218, No 12. - P. 1900-1910. doi: 10.1093/infdis/jiy432Sexual Activity-Related Outcomes After Human Papillomavirus Vaccination of 11- to 12-Year-Olds / R.A. Bednarczyk [et al.] // Pediatrics. - 2012. - Vol. 130, No 5. - P. 798-805. doi: 10.1542/peds.2012-1516)Sexual Activity-Related Outcomes After Human Papillomavirus Vaccination of 11- to 12-Year-Olds / R.A. Bednarczyk [et al.] // Pediatrics. - 2012. - Vol. 130, No 5. - P. 798-805. doi: 10.1542/peds.2012-1516)Safety and perception: What are the greatest enemies of HPV vaccination programmes? / P. Bonanni [et al.] // Vaccine. - 2018. - Vol. 36, No 36. - P. 5424- 5429. doi: 10.1016/j.vaccine.2017.05.071Safety and perception: What are the greatest enemies of HPV vaccination programmes? / P. Bonanni [et al.] // Vaccine. - 2018. - Vol. 36, No 36. - P. 5424- 5429. doi: 10.1016/j.vaccine.2017.05.071Parenting Style and the Timing of Jewish Adolescents’ Sexual Debut / R. Etzkin [et al.] // Journal of Youth Development. - 2010. - Vol. 5, No 2. - P. 17. doi: 10.5195/jyd.2010.216Parenting Style and the Timing of Jewish Adolescents’ Sexual Debut / R. Etzkin [et al.] // Journal of Youth Development. - 2010. - Vol. 5, No 2. - P. 17. doi: 10.5195/jyd.2010.216Knowledge and Attitudes Towards Human Papillomavirus (HPV) Among Academic and Community Physicians in Mangalore, India / C. Canon [et al.] // Cancer Education. - 2017. - Vol. 32, No 2. - P. 382-391. doi: 10.1007/s13187-016-0999-0Knowledge and Attitudes Towards Human Papillomavirus (HPV) Among Academic and Community Physicians in Mangalore, India / C. Canon [et al.] // Cancer Education. - 2017. - Vol. 32, No 2. - P. 382-391. doi: 10.1007/s13187-016-0999-0Parents’ uptake of human papillomavirus vaccines for their children: a systematic review and meta-analysis of observational studies / P.A. Newman [et al.] // BMJ Open. - 2018. - Vol. 8, No 4. doi: 10.1136/bmjopen-2017-019206Parents’ uptake of human papillomavirus vaccines for their children: a systematic review and meta-analysis of observational studies / P.A. Newman [et al.] // BMJ Open. - 2018. - Vol. 8, No 4. doi: 10.1136/bmjopen-2017-019206No Association between HPV Vaccination and Infertility in U.S. Females 18-33 Years Old / N.B. Schmuhl [et al.] // Vaccine. - 2020. - Vol. 38, No 24. - P. 4038- 4043. doi:10.1016/j.vaccine.2020.03.035No Association between HPV Vaccination and Infertility in U.S. Females 18-33 Years Old / N.B. Schmuhl [et al.] // Vaccine. - 2020. - Vol. 38, No 24. - P. 4038- 4043. doi:10.1016/j.vaccine.2020.03.035HPV infection and bacterial microbiota in the placenta, uterine cervix and oral mucosa / H. Tuominen [et al.] // Scientific Reports. - 2018. - Vol. 8, No 1. - P. 9787. doi:10.1038/s41598-018-27980-3HPV infection and bacterial microbiota in the placenta, uterine cervix and oral mucosa / H. Tuominen [et al.] // Scientific Reports. - 2018. - Vol. 8, No 1. - P. 9787. doi:10.1038/s41598-018-27980-3Juvenile-Onset Recurrent Respiratory Papillomatosis Diagnosis and Management - A Developing Country Review / R. Seedat // Pediatric Health, Medicine and Therapeutics. - 2020. - Vol. 11. - P. 39-46. doi:10.2147/PHMT.S200186Juvenile-Onset Recurrent Respiratory Papillomatosis Diagnosis and Management - A Developing Country Review / R. Seedat // Pediatric Health, Medicine and Therapeutics. - 2020. - Vol. 11. - P. 39-46. doi:10.2147/PHMT.S200186Paediatric virology and human papillomaviruses: An update / I.N. Mammas [et al.] // Experimental and Therapeutic Medicine. - 2019. - Vol. 17, No 6. - P. 4337-4343. doi: 10.3892/etm.2019.7516Paediatric virology and human papillomaviruses: An update / I.N. Mammas [et al.] // Experimental and Therapeutic Medicine. - 2019. - Vol. 17, No 6. - P. 4337-4343. doi: 10.3892/etm.2019.7516Recurrent respiratory papillomatosis: A state-of-the-art review / H.R. Fortes [et al.] // Respiratory Medicine. - 2017. - Vol. 126. - P. 116-121. doi:10.1016/j.rmed.2017.03.030Recurrent respiratory papillomatosis: A state-of-the-art review / H.R. Fortes [et al.] // Respiratory Medicine. - 2017. - Vol. 126. - P. 116-121. doi:10.1016/j.rmed.2017.03.030Is HPV the Novel Target in Male Idiopathic Infertility? A Systematic Review of the Literature / F. Muscianisi [et al.] // Frontiers in Endocrinology. - 2021. - Vol. 12. doi: 10.3389/fendo.2021.643539Is HPV the Novel Target in Male Idiopathic Infertility? A Systematic Review of the Literature / F. Muscianisi [et al.] // Frontiers in Endocrinology. - 2021. - Vol. 12. doi: 10.3389/fendo.2021.643539Idiopathic male infertility and human papillomavirus infection / K.S. Ibishev [et al.] // Vestnik Urologii. - 2019. - Vol. 7, No 2. - P. 51-58. doi: 10.21886/2308-6424-2019-7-2-51-58Idiopathic male infertility and human papillomavirus infection / K.S. Ibishev [et al.] // Vestnik Urologii. - 2019. - Vol. 7, No 2. - P. 51-58. doi: 10.21886/2308-6424-2019-7-2-51-58Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): Health system experiences and prospects /j. Wigle [et al.] // Vaccine. - 2013. - Vol. 31, No 37. - P. 3811-3817. doi: 10.1016/j.vaccine.2013.06.016Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): Health system experiences and prospects /j. Wigle [et al.] // Vaccine. - 2013. - Vol. 31, No 37. - P. 3811-3817. doi: 10.1016/j.vaccine.2013.06.016Is one dose of human papillomavirus vaccine as effective as three? : A national cohort analysis /j.M.L. Brotherton [et al.] // Papillomavirus Research. - 2019. - Vol. 8. doi: 10.1016/j.pvr.2019.100177Is one dose of human papillomavirus vaccine as effective as three? : A national cohort analysis /j.M.L. Brotherton [et al.] // Papillomavirus Research. - 2019. - Vol. 8. doi: 10.1016/j.pvr.2019.100177Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact / V. Gilca [et al.] // Vaccine. - 2018. - Vol. 36, No 32. - P. 4800-4805. doi:10.1016/j.vaccine.2018.02.004Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact / V. Gilca [et al.] // Vaccine. - 2018. - Vol. 36, No 32. - P. 4800-4805. doi:10.1016/j.vaccine.2018.02.004Towards the global elimination of cervical cancer / K. Canfell // Papillomavirus Research. - 2019. - Vol. 8. - P. 100170. doi: 10.1016/j.pvr.2019.100170Towards the global elimination of cervical cancer / K. Canfell // Papillomavirus Research. - 2019. - Vol. 8. - P. 100170. doi: 10.1016/j.pvr.2019.100170General practitioners’ attitudes and behaviors toward HPV vaccination: A French national survey / F. Collange [et al.] // Vaccine. - 2016. - Vol. 34, No 6. - P. 762-768. doi: 10.1016/j.vaccine.2015.12.054General practitioners’ attitudes and behaviors toward HPV vaccination: A French national survey / F. Collange [et al.] // Vaccine. - 2016. - Vol. 34, No 6. - P. 762-768. doi: 10.1016/j.vaccine.2015.12.054

The authors declare that there are no conflicts of interest present.